Why Telehealth Stocks Just Tumble After Medicare's Policy Shift

Telehealth services seemed poised for sustained growth. The convenience of receiving medical care from home, coupled with time and cost savings for both physicians and patients, appeared to create a lasting market advantage. Yet shares of major telehealth providers like Teladoc Health (NYSE: TDOC) and Doximity (NYSE: DOCS) have failed to reflect this promise. As of early 2026, the outlook grows even more challenging following significant policy changes.

Medicare’s New Reimbursement Rules Take Effect

During the pandemic, government policies expanded telehealth access dramatically. Medicare began reimbursing patients for virtual care services received anywhere, including from home—a critical expansion that supported industry growth. However, those temporary provisions expired on January 31, 2026. The new reimbursement framework now limits coverage to patients receiving telehealth services from healthcare facilities, rural areas, or accessing virtual mental health services. Home-based routine telemedicine visits in non-rural areas no longer qualify for Medicare reimbursement.

This policy reversal represents a fundamental shift in the market dynamics that previously supported telehealth adoption. Many industry watchers predicted such a downturn, but the actual implementation of these restrictions now makes the headwinds concrete rather than theoretical.

Teladoc Health’s Continued Struggles

Teladoc, as a pure-play telehealth company, faces the most direct impact from Medicare’s narrowed coverage. The company’s revenue growth had already been sluggish even before this policy change. While Teladoc maintains an extensive patient network and doesn’t depend solely on Medicare reimbursement, the company’s broader challenges make this development particularly problematic.

The organization remains unprofitable and continues wrestling with insufficient third-party reimbursement for BetterHelp, its virtual therapy platform. These operational weaknesses, combined with the reduced Medicare coverage, substantially darken Teladoc’s near-term prospects. Though international expansion efforts show some promise, with international revenue growing faster than domestic segments, the accumulated headwinds appear formidable. Market observers increasingly question whether the company can achieve profitability before additional obstacles emerge.

Doximity Faces Headwinds Despite Diversification

Doximity operates under a different business model than Teladoc, which provides some insulation from this particular policy shift. Beyond telemedicine, Doximity offers a physician networking platform, professional news services, and marketing channels for pharmaceutical companies and healthcare systems. Revenue streams come from subscriptions paid by pharmaceutical companies and health systems seeking physician engagement, alongside its telemedicine tools.

However, Doximity confronts its own set of challenges. Though profitable, the company’s revenue growth has decelerated substantially over recent years, falling short of market expectations and triggering notable stock price declines. With roughly 80% of U.S. physicians already using its platform, expansion momentum has slowed considerably. The company struggles to replicate its earlier growth trajectory, suggesting that peak growth rates may not return.

For both companies, the Medicare policy change arrives at an inopportune moment, even as each battles distinct operational pressures that make recovery uncertain.